BCG vaccination in Korea, Japan, and Taiwan: Current status and future perspectives

Citations

WEB OF SCIENCE

0
Citations

SCOPUS

0

초록

The Bacille Calmette–Guérin (BCG) vaccine remains essential for preventing severe pediatric tuberculosis (TB). This review compares BCG policies in Korea, Japan, and Taiwan–three low-burden countries with differing strategies. Notably, Taiwan and Japan have delayed vaccination to 5–8 months specifically to mitigate osteitis risks, whereas Korea retains a schedule before four weeks. Despite these variations in timing and vaccine strains, all three nations maintain >95% coverage and have effectively eliminated severe pediatric TB. These outcomes suggest that varying delivery models can achieve comparable success. However, as epidemiological landscapes transition, the focus must shift toward enhanced safety surveillance and programmatic precision. Reassessing vaccination policies is crucial to minimize adverse events while maintaining protection against severe disease in low-burden settings.

키워드

BCG; tuberculosis; vaccination policy; immunization program; Korea; Japan; Taiwan; CALMETTE-GUERIN VACCINATION; SAFETY SURVEILLANCE; ADVERSE EVENTS; GLOBAL BURDEN; TOKYO-STRAIN; TUBERCULOSIS; CHILDREN; IMMUNIZATION; MORTALITY; VIABILITY
제목
BCG vaccination in Korea, Japan, and Taiwan: Current status and future perspectives
저자
Choe, Young June; Kim, Keun Ju; Yoshida, Lay-Myint; Toizumi, Michiko; Lin, Yung-Ching
DOI
10.1080/21645515.2026.2650048
발행일
2026-12
유형
Review
저널명
Human Vaccines and Immunotherapeutics
권
22
호
1